To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
It is unclear to what extent the traditional distinction between
neurological and psychiatric disorders reflects biological
To examine neuroimaging evidence for the distinction between neurological
and psychiatric disorders.
We performed an activation likelihood estimation meta-analysis on
voxel-based morphometry studies reporting decreased grey matter in 14
neurological and 10 psychiatric disorders, and compared the regional and
network-level alterations for these two classes of disease. In addition,
we estimated neuroanatomical heterogeneity within and between the two
Basal ganglia, insula, sensorimotor and temporal cortex showed greater
impairment in neurological disorders; whereas cingulate, medial frontal,
superior frontal and occipital cortex showed greater impairment in
psychiatric disorders. The two classes of disorders affected distinct
functional networks. Similarity within classes was higher than between
classes; furthermore, similarity within class was higher for neurological
than psychiatric disorders.
From a neuroimaging perspective, neurological and psychiatric disorders
represent two distinct classes of disorders.
There is an ongoing debate about the use of atypical antipsychotics as a first-line treatment for first-episode psychosis.
To examine the evidence base for this recommendation.
Meta-analyses of randomised controlled trials in the early phase of psychosis, looking at long-term discontinuation rates, short-term symptom changes, weight gain and extrapyramidal side-effects. Trials were identified using a combination of electronic (Cochrane Central, EMBASE, MEDLINE and PsycINFO) and manual searches.
Fifteen randomised controlled trials with a total of 2522 participants were included. No significant differences between atypical and typical drugs were found for discontinuation rates (odds ratio (OR) = 0.7, 95% CI 0.4 to 1.2) or effect on symptoms (standardised mean difference (SMD) = –0.1, 95% CI –0.2 to 0.02). Participants on atypical antipsychotics gained 2.1 kg (95% CI 0.1 to 4.1) more weight than those on typicals, whereas those on typicals experienced more extrapyramidal side-effects (SMD = –0.4, 95% CI –0.5 to –0.2).
There was no evidence for differences in efficacy between atypical and typical antipsychotics, but there was a clear difference in the side-effect profile.
Email your librarian or administrator to recommend adding this to your organisation's collection.